These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Effect of simvastatin on cetuximab resistance in human colorectal cancer with KRAS mutations. Lee J; Lee I; Han B; Park JO; Jang J; Park C; Kang WK J Natl Cancer Inst; 2011 Apr; 103(8):674-88. PubMed ID: 21398618 [TBL] [Abstract][Full Text] [Related]
25. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Maughan TS; Adams RA; Smith CG; Meade AM; Seymour MT; Wilson RH; Idziaszczyk S; Harris R; Fisher D; Kenny SL; Kay E; Mitchell JK; Madi A; Jasani B; James MD; Bridgewater J; Kennedy MJ; Claes B; Lambrechts D; Kaplan R; Cheadle JP; Lancet; 2011 Jun; 377(9783):2103-14. PubMed ID: 21641636 [TBL] [Abstract][Full Text] [Related]
26. PTEN gene expression and mutations in the PIK3CA gene as predictors of clinical benefit to anti-epidermal growth factor receptor antibody therapy in patients with KRAS wild-type metastatic colorectal cancer. Sood A; McClain D; Maitra R; Basu-Mallick A; Seetharam R; Kaubisch A; Rajdev L; Mariadason JM; Tanaka K; Goel S Clin Colorectal Cancer; 2012 Jun; 11(2):143-50. PubMed ID: 22285706 [TBL] [Abstract][Full Text] [Related]
28. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis. Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682 [TBL] [Abstract][Full Text] [Related]
29. Is there a role for IGF1R and c-MET pathways in resistance to cetuximab in metastatic colorectal cancer? Inno A; Di Salvatore M; Cenci T; Martini M; Orlandi A; Strippoli A; Ferrara AM; Bagalà C; Cassano A; Larocca LM; Barone C Clin Colorectal Cancer; 2011 Dec; 10(4):325-32. PubMed ID: 21729677 [TBL] [Abstract][Full Text] [Related]
30. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study. Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966 [TBL] [Abstract][Full Text] [Related]
31. EGFR gene copy number predicts response to anti-EGFR treatment in RAS wild type and RAS/BRAF/PIK3CA wild type metastatic colorectal cancer. Ålgars A; Sundström J; Lintunen M; Jokilehto T; Kytölä S; Kaare M; Vainionpää R; Orpana A; Österlund P; Ristimäki A; Carpen O; Ristamäki R Int J Cancer; 2017 Feb; 140(4):922-929. PubMed ID: 27879995 [TBL] [Abstract][Full Text] [Related]
32. Activity and Safety of Cetuximab Plus Modified FOLFOXIRI Followed by Maintenance With Cetuximab or Bevacizumab for RAS and BRAF Wild-type Metastatic Colorectal Cancer: A Randomized Phase 2 Clinical Trial. Cremolini C; Antoniotti C; Lonardi S; Aprile G; Bergamo F; Masi G; Grande R; Tonini G; Mescoli C; Cardellino GG; Coltelli L; Salvatore L; Corsi DC; Lupi C; Gemma D; Ronzoni M; Dell'Aquila E; Marmorino F; Di Fabio F; Mancini ML; Marcucci L; Fontanini G; Zagonel V; Boni L; Falcone A JAMA Oncol; 2018 Apr; 4(4):529-536. PubMed ID: 29450468 [TBL] [Abstract][Full Text] [Related]
33. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110 [TBL] [Abstract][Full Text] [Related]
34. Impact of BRAF and RAS mutations on first-line efficacy of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab: analysis of the FIRE-3 (AIO KRK-0306) study. Stintzing S; Miller-Phillips L; Modest DP; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Held S; Moehler M; Jagenburg A; Kirchner T; Jung A; Heinemann V; Eur J Cancer; 2017 Jul; 79():50-60. PubMed ID: 28463756 [TBL] [Abstract][Full Text] [Related]
35. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected. Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E; Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676 [TBL] [Abstract][Full Text] [Related]
36. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer. Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936 [TBL] [Abstract][Full Text] [Related]
37. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. De Roock W; Jonker DJ; Di Nicolantonio F; Sartore-Bianchi A; Tu D; Siena S; Lamba S; Arena S; Frattini M; Piessevaux H; Van Cutsem E; O'Callaghan CJ; Khambata-Ford S; Zalcberg JR; Simes J; Karapetis CS; Bardelli A; Tejpar S JAMA; 2010 Oct; 304(16):1812-20. PubMed ID: 20978259 [TBL] [Abstract][Full Text] [Related]
38. RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal Cancer. Schrock AB; Lee JK; Sandhu J; Madison R; Cho-Phan C; Snider JW; Castellanos E; Venstrom JM; Fakih M Oncologist; 2021 Jun; 26(6):469-475. PubMed ID: 33465286 [TBL] [Abstract][Full Text] [Related]